Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Neumora Therapeutics, Inc. roe for the quarter ending 2026-06-30 was -477.87%, a change of -340.03% year-over-year.
Neumora Therapeutics, Inc. roe for the quarter ending 2026-03-31 was -314.65%, a change of -201.65% year-over-year.
Neumora Therapeutics, Inc. roe for the quarter ending 2025-12-31 was -228.10%, a change of -143.17% year-over-year.
Neumora Therapeutics, Inc. roe for the quarter ending 2025-09-30 was -178.79%, a change of -87.23% year-over-year.
Neumora Therapeutics, Inc. roe for fiscal 2025 was -228.10%, a change of -143.17% from fiscal 2024.
Neumora Therapeutics, Inc. roe for fiscal 2024 was -84.92%, a change of -34.63% from fiscal 2023.
Neumora Therapeutics, Inc. roe for fiscal 2023 was -50.30%, a 271.69% decline from fiscal 2022.
Neumora Therapeutics, Inc. roe for fiscal 2022 was 29.29%.